Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Incidence of pandemic influenza and the immunogenicity of the pandemic vaccin.

- candidate number6275
- NTR NumberNTR2070
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR4-aug-2009
- Secondary IDs255/29241.000.09 NVI/NL
- Public TitleIncidence of pandemic influenza and the immunogenicity of the pandemic vaccin.
- Scientific TitleNew Influenza A (H1N1) disease incidence and immunogenicity of the pandemic influenza A (H1N1) vaccin in healthy adults.
- hypothesisEvaluation of pandemic influenza incidence of vaccinated subjects compared to unvaccinated subjects in correlation with immunogenicity of the vaccine.
- Healt Condition(s) or Problem(s) studiedInfluenza, Pandemia H1N1
- Inclusion criteria1. Good self-reported health according to the investigator;
2. Willingness and ability to adhere to the study regimen;
3. Having a signed informed consent (IC) form;
4. Age 18 65 years.
- Exclusion criteriaThe exclusion criteria with regard to contra-indications for receiving the pandemic influenza vaccine are:
1. Allergy to any of the components of the vaccine or trace residues of eggs, chicken proteins, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB).

The exclusion criteria with regard to blood collection and the immunological analysis are:
1. Immune deficiencies;
2. Haematological disorders;
3. Bleeding disorders;
4. Usage of anticoagulants, corticosteroids, NSAIDs and/or statins;
5. Diabetes mellitus;
6. Having had an infectious disease with fever within the last two weeks;
7. Previously diagnosed with pandemic H1N1 influenza.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 26-okt-2009
- planned closingdate31-dec-2010
- Target number of participants375
- InterventionsHealthy adults will be vaccinated 2 times with a 3 week interval with the pandemic influenza vaccin Focetria (Novartis). At the described timepoints blood sampling will take place for immunological analysis. In the control group, individuals will not be vaccinated and bloodsampling will take place at timepoint 1 and 6.
In both groups, a nose swab will be taken when an individual reports influenza-like symptoms to confirm the presence of pandemic H1N1 virus. Primary endpoint of the study is the difference in the percentage of individuals infected with the pandemic influenza virus in both arms of the study.
- Primary outcomeEvaluation of pandemic influenza incidence of vaccinated subjects compared to unvaccinated subjects.
- Secondary outcome1. Obtain data on immunogenicity of pandemic influenza vaccination;
a. Evaluation of the humoral immune response to the vaccine and correlate this to protection against the virus;
b. Evaluation of the cellular response to the vaccines and correlate this to protection against the virus;
c. Evaluation of the response to the second dose of the pandemic influenza vaccine.
2. Evaluation of cross-specific immune responses to pandemic H1N1 virus in the pre-vaccination samples;
3. Evaluation of specific immune responses against pandemic H1N1 virus in infected, unvaccinated controls;
4. Obtain data on immunogenicity of adjuvanted pandemic influenza A (H1N1) vaccination more than one year after vaccination;
5. Evaluation of the boosting capacity of unadjuvanted seasonal influenza A (H1N1) vaccination;
6. Evaluation of humoral and cellular immune responses against influenza A (H3N2) vaccine.
- TimepointsTimepoint 1: Presample blood and first vaccination;
Timepoint 2: Bloodsample 10-14 days after vaccination;
Timepoint 3: Bloodsample 3 weeks after first vaccination and second vaccination;
Timepoint 4: Blood sampling 3 weeks after second vaccination;
Timepoint 5: Nose swab, applicable if influenza-like illness is reported;
Timepoint 6: Bloodsampling at end of pandemic;
Timepoint 7: Bloodsample 1 year after vaccination;
Timepoint 8: Bloodsample 3 weeks after timepoint 7 (if additional influenza vaccination is administered);
Timepoint 9: Bloodsample at end of influenza season 2010/2011.
- Trial web siteN/A
- statusopen: patient inclusion
- Sponsor/Initiator Nederlands Vaccin Instituut (NVI)
- Funding
(Source(s) of Monetary or Material Support)
Ministry of Health, Welfare and Sports (VWS)
- PublicationsN/A
- Brief summaryWe will investigate the incidence of pandemic influenza in healthy adults between 18 and 52 years of age that have either received the pandemic influenza vaccine or not and analyze whether humoral and cellular immune responses correlate with protection against influenza. The findings will have important implications for future pandemic and seasonal influenza vaccination campaigns.
- Main changes (audit trail)
- RECORD4-aug-2009 - 24-okt-2010

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar